Biofrontera announces preliminary revenues for the month of
Leverkusen, Germany, September 08, 2021 (GLOBE NEWSWIRE) – Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), a global biopharmaceutical company, today announced unaudited preliminary revenue for August 2021.
The Company’s unaudited preliminary revenue from product sales in August 2021 was approximately 1,485 thousand euros, compared to 1,341 thousand euros in August 2020, an increase of 11%.
Preliminary revenue from product sales in the United States was approximately 1,027 thousand euros compared to 917 thousand euros in August 2020, an increase of 12%. In Germany, product sales revenue amounted to around 349 thousand euros, compared to 345 thousand euros in August 2020, a slight increase of 1%. In the rest of Europe, the Company generated product sales of approximately 109 thousand euros, compared to 79 thousand euros in August 2020, an increase of 38%.
Preliminary unaudited revenues
|August||January – August|
|in thousands of euros||2021||2020||2019||2021||2020||2019|
|Europe (excluding Germany)||109||79||103||2.016||1,200||1,670|
|Total revenue from product sales||1,485||1341||1342||16 149||12,539||16,526|
|Revenues from R&D projects and license payments||0||0||48||0||6,493||323|
|Total income||1,485||1341||1,391||16 149||19,032||16,849|
Due to commercial rounding, rounding differences may appear in the tables.
Due to the pandemic, the evolution of monthly and annual sales is compared to 2019 sales for increased transparency. Thus, an 11% increase in total product sales in August 2021 was achieved in all markets compared to August 2019. In the United States, product sales increased by approximately 4% compared to August 2019. In August 2021, product sales increased by around 36% in Germany and product sales in other European markets increased by around 7% compared to August 2019.
Compared to 2019, product sales in all markets have decreased by approximately 2% compared to sales for the period January to August 2021. Product sales since the start of 2021 have increased by approximately 25% in Germany and 21% the rest of the year. the European market compared to the same period in 2019. The turnover of products in the US market fell by 12%, mainly due to the weak sales of the months of January and February of this year due to the pandemic as well only the lack or the decline in sales of Aktipak® and Xépi® compared to the period from January to August 2019.
Pamela Keck, Head of Investor Relations
Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.
The German-based company, with more than 150 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company’s flagship product is the combination of Ameluz®, a topical prescription drug and a BF-RhodoLED medical device® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the US since May 2016. In addition, the company markets the prescription drug Xepi® for the treatment of impetigo in the United States. In the EU, the company also sells the Belixos dermocosmetics series®, which offers specialized care for damaged or diseased skin.
Biofrontera is the first German pharmaceutical company headed by a founder to receive centralized European and American approval for a drug developed in-house. The Biofrontera group was founded in 1997 by the current CEO, Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and the US NASDAQ www.biofrontera.com.
Forward-looking statements: Certain statements contained in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of the proceeds from the offering.
These statements can be identified by the use of forward-looking words such as “anticipate”, “believe”, “expect”, “estimate” and “intend”, among others. These forward-looking statements are based on beliefs and assumptions currently held by the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company, or the results of the industry to differ. significantly results, financial position, performance or achievements. expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are set out in the Annual Report on Form 20-F filed with the SEC, including Item 3.D. “Key Information – Risk Factors” and in future reports filed with the SEC. In light of these risks, uncertainties and other factors, potential investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake to update or revise any forward-looking statement.